Brief: Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA(pembrolizumab)
17/10/2023 14:48
Oct 17 (Reuters) - Kineta Inc KA.O :
* KINETA ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2
VISTA-101
CLINICAL TRIAL OF KVA12123 IN COMBINATION WITH KEYTRUDA®
(PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED SOLID TUMORS
* KINETA INC - INITIAL COMBINATION THERAPY CLINICAL DATA
ANTICIPATED IN Q2 2024
Source text for Eikon: ID:nGNX6sMlyk
Further company coverage: KA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kineta
See all newsBrief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study